Grenoble University hospital
Grenoble, 38043, France
NCT Number: NCT02316665
Hypothesis: To address the role of continuous positive airway pressure (CPAP)on nocturnal glycemia in patients having type 1 diabetes and sleep apnea syndrome.
Investigators make the hypothesis that sleep apnea syndrome impacts nocturnal glycemia in type 1 diabetic patients and that continuous positive airway pressure treatment will permit to improve the nocturnal glycemic profile.
Study design: Adult patients with type 1 diabetes will be recruited for an extensive study of sleep habits and assessment of sleep breathing disorders. When patients will present with severe sleep apnea syndrome (apnea-hypopnea index above 30 events/hour) and insufficient glycemic control (HbA1c > 7.5%), they will be randomized in continuous positive airway pressure treatment or sham-continuous positive airway pressure treatment group for three months.
Main outcome: Nocturnal glycemic control will be assessed for 5 days before and after three months of the allocated treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Grenoble, 38043, France
Quality of clinical study procedures will be checked by on-site audit.
Patient self-reported past medical history will be checked by reviewing medical records.
Paper case report forms will be used.
For the baseline extensive study of sleep habits, the following data are recorded:
Blood measurements: HbA1c, lipidic profile, microalbuminuria, creatinin
After baseline assessment, patients having an abnormal nocturnal oximetry will be explored by polysomnography in order to detect a sleep apnea syndrome.
Investigators anticipate, based on a previous pilot study of our group ("Borel" Diab Med 2010), that 30% of screened patients will present with sleep apnea.
If patients present with severe sleep apnea (IAH > 30 events/hour) and HbA1c > 7.5%, they will be randomized for the intervention.
Sample size: based on a previous study by "Pallayova" et al. in patients having type 2 diabetes, investigators anticipate a difference between groups of 1.3 (SD 2.07) for the mean nocturnal glycemia. For a alpha threshold of 5% and a study power of 80%, the study should include 32 patients in each group. Taking in account a possible 25% of dropout the study will need to include 40 patients by randomized arm to demonstrate an effect.
Statistical analysis: An intention-to-treat analysis will be performed. Missing data for the continuous positive airway pressure group will be replaced by the median value at three-month of the sham-continuous positive airway pressure group and reciprocally.
In a second analysis, a per-protocol analysis will be performed limited to patients having completed their treatment in allocated group and having an adherence to continuous positive airway pressure or sham-continuous positive airway pressure treatment for more than 4-hours a night.
Normality of data will be checked by Kurtosis and Skewness tests. The significance level will be set at 5%.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
continuous positive airway pressure treatment during three months with adherence recording
Sham-continuous positive airway pressure during three months with adherence recording
Time frame: 3 months
Measured from continuous glycemic monitoring system
Time frame: 3 months
24h ambulatory blood pressure monitoring
Time frame: 3months
Measured on nighttime recording of continuous glycemic monitoring system
Time frame: 3 months
Time frame: 3 months
Actimetry
Time frame: 3 months
Self-monitoring blood pressure and heart rate device, at home
Time frame: 3 months
Actimetry
Time frame: 3 months
Actimetry
Time frame: 3 months
Self-monitoring blood pressure and heart rate device, at home
Time frame: 3 months
Self-monitoring blood pressure and heart rate device, at home
University Hospital, Grenoble
Other
Effect of Continuous Positive Airway Pressure Treatment on Nocturnal Glycemia of Patients Having Type 1 Diabetes and Sleep Apnea Syndrome: a Randomized Controlled Trial
Acronym: DIADEME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05488119
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT07696780
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT05610111
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06308549
Autoimmune Diseases, Diabetes Distress
Bad Mergentheim, Baden-Wurttemberg, Germany
View Trial Details